Search

Your search keyword '"Vanesa Gregorc"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Vanesa Gregorc" Remove constraint Author: "Vanesa Gregorc" Publisher american society of clinical oncology (asco) Remove constraint Publisher: american society of clinical oncology (asco)
45 results on '"Vanesa Gregorc"'

Search Results

1. AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC

2. A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results

Catalog

Books, media, physical & digital resources

3. Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM)

4. Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

5. Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study

6. Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)

7. Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015

8. Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial

9. Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) enrolled in the NGR015 phase 3 trial

10. Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)

11. Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): Findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC

12. Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC)

13. Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy

14. Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM)

15. Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT)

16. Infusion-related reactions (IRR) during NGR-hTNF therapy as potential predictors of clinical outcome

17. Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC)

18. Treatment-free interval (TFI) after first-line therapy (FLT) and disease control rate (DCR) on second-line therapy (SLT): Impact on overall survival (OS) in relapsed malignant pleural mesothelioma (MPM)

19. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE)

20. A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC)

21. NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC)

22. NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)

23. GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC

24. NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC)

25. Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC)

26. PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC)

27. NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)

28. Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results

29. Predictive potential of angiogenic plasma biomarkers (PBs) in phase I trial with NGR-hTNF

30. Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)

31. Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM)

32. Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)

33. Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

34. Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors

35. A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

36. NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study

37. A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)

38. A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors

39. Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report

40. Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)

41. Optimal safety profile and anticancer activity of NGRhTNF coupled with doxorubicin (NGR003 modified phase I combo trial)

42. Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum

43. Association of germline mutations in EGFR and ABCG2 with gefitinib response in patients with non-small cell lung cancer (NSCLC)

44. Single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: Preliminary results of a phase II randomized trial

45. Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer